Summary
Eli Lilly and Company (LLY) reported a net loss of $465.6 million for the third quarter of 2008, a significant shift from the same period in the prior year which saw a net income of $926.3 million. This loss was heavily influenced by a substantial $1.48 billion charge related to the resolution of investigations concerning Zyprexa marketing and promotion practices. Despite the quarterly loss, year-to-date net income stood at $1.56 billion, down from $2.10 billion in the first nine months of 2007, also impacted by significant charges and lower year-over-year performance. Top-line growth remained robust, with worldwide sales increasing by 14% in the third quarter and 13% for the first nine months, driven by key products like Cymbalta, Alimta, Cialis, Humalog, and Gemzar, along with favorable foreign exchange rates. However, investors should note the significant impact of legal settlements and restructuring charges on profitability. The company also announced a significant subsequent event: a definitive merger agreement to acquire ImClone Systems for approximately $6.5 billion, signaling a strategic move into the oncology space.
Financial Highlights
22 data pointsKey Highlights
- 1Third-quarter net loss of $465.6 million, compared to a net income of $926.3 million in Q3 2007, primarily due to a $1.48 billion charge for Zyprexa investigations.
- 2Year-to-date net income of $1.56 billion, down 26% from $2.10 billion in the same period last year, impacted by significant charges.
- 3Worldwide sales increased by 14% in Q3 2008 and 13% year-to-date, driven by strong performance of key products like Cymbalta, Alimta, Cialis, Humalog, and Gemzar.
- 4Significant charges included $1.48 billion for Zyprexa investigations, $182.4 million for restructuring and asset impairments, and $28.0 million for acquired in-process R&D.
- 5The company announced its intent to acquire ImClone Systems for approximately $6.5 billion, a major strategic move into the oncology sector.
- 6Cash and cash equivalents, along with short-term investments, increased to $6.12 billion as of September 30, 2008, providing financial flexibility.
- 7Ongoing patent litigation for key products like Cymbalta, Gemzar, Alimta, Evista, and Strattera poses potential future risks, though the company expects to prevail.